March 27th 2024
During a Case-Based Roundtable® event, David Zhen, MD, discussed the issue of treating patients with upper gastrointestinal cancer with a PD-L1 composite positive score less than 5 with nivolumab vs chemotherapy alone, in the first article of a 2-part series.
What’s in Your Basket? Tumor Agnostic Trials and the Reshaping of Precision Medicine in Oncology: A Focus on TSC1/2 Mutations
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Exploring MRI-Guided Adaptive Radiation to Treat Inoperable Pancreatic Cancer
October 6th 2021In an interview with Targeted Oncology™, Michael Chuong, MD explained of the validity of the MRI-guided radiation technique for use in patients with pancreatic cancer, how it compares with CT-guided radiation, and how a shift toward MRI-guided radiation may impact patients with pancreatic cancer in the future.
Read More
Benefits of MRI-Directed Ablative Radiotherapy in Pancreatic Cancer
September 16th 2021Michael D. Chuong, MD, a radiation oncologist and medical director of Proton Therapy at Miami Cancer Institute, Baptist Health South Florida, discusses the benefits of MRI-guided radiation therapy in pancreatic cancer.
Watch
MRI-Guided Radiation Therapy: A Novel Treatment for Pancreatic Cancer
September 16th 2021Complete surgical removal of a pancreatic tumor is not possible for most patients. Chemotherapy and radiation therapy are typically recommended to slow tumor growth, but ultimately are not expected to be curative, writes Michael Chuong, MD.
Read More
Tislelizumab Metastatic ESCC BLA Now Under FDA Consideration for Approval
September 13th 2021The FDA has accepted the biologics license application for tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of unresectable recurrent locally advanced or metastatic esophageal squamous cell carcinoma in previously treated patients.
Read More
New Therapies Challenge SOC in Genitourinary Cancers
August 25th 2021In an interview with Targeted Oncology™, Guru Sonpavde, MD, discussed the safety and efficacy of fixed-dose durvalumab for UTC along with an overview of the ongoing CheckMate 274 trial, which evaluates nivolumab compared to placebo in this patient population.
Read More
Sintilimab Plus Chemotherapy Doublet Extends OS in Advanced Gastric and GEJ Cancers
August 16th 2021Sintilimab in combination with the chemotherapy agents oxaliplatin and capecitabine improved overall survival in patients with unresectable, locally advanced, recurrent, or metastatic gastric or gastroesophageal junction adenocarcinoma compared with chemotherapy alone, reaching the predefined primary end point of the phase 2 ORIENT-16 clinical trial.
Read More
First Patient Dosed in AVB-500 Trial For Pancreatic Adenocarcinoma
August 13th 2021The first patient has been dosed in a phase 1b/2 trial of AVB-500, a therapeutic recombinant fusion protein, in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic adenocarcinoma.
Read More
Adding Immunotherapy to Perioperative Chemotherapy For Gastroesophageal Cancer Beneficial
August 12th 2021In an interview with Targeted Oncology, Thierry Alcindor, MD, discusses the benefits of adding avelumab to perioperative chemotherapy for the treatment of gastroesophageal cancer in greater detail.
Read More
FDA Denies Approval of Retifanlimab for Locally Advanced or Metastatic SCAC Subgroup
July 26th 2021The FDA issued a complete response letter to Incyte Corporation in response to the Biologics License Application for the PD-L1 inhibitor, retifanlimab for the treatment of adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal who have progressed on, or who are intolerant of, platinum-based chemotherapy.
Read More